Correlation Between Citigroup and Orphazyme

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Citigroup and Orphazyme at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Citigroup and Orphazyme into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Citigroup and Orphazyme AS, you can compare the effects of market volatilities on Citigroup and Orphazyme and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Citigroup with a short position of Orphazyme. Check out your portfolio center. Please also check ongoing floating volatility patterns of Citigroup and Orphazyme.

Diversification Opportunities for Citigroup and Orphazyme

-0.18
  Correlation Coefficient

Good diversification

The 3 months correlation between Citigroup and Orphazyme is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding Citigroup and Orphazyme AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Orphazyme AS and Citigroup is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Citigroup are associated (or correlated) with Orphazyme. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Orphazyme AS has no effect on the direction of Citigroup i.e., Citigroup and Orphazyme go up and down completely randomly.

Pair Corralation between Citigroup and Orphazyme

Taking into account the 90-day investment horizon Citigroup is expected to generate 7.68 times less return on investment than Orphazyme. But when comparing it to its historical volatility, Citigroup is 2.68 times less risky than Orphazyme. It trades about 0.01 of its potential returns per unit of risk. Orphazyme AS is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  107,500  in Orphazyme AS on February 6, 2024 and sell it today you would earn a total of  2,200  from holding Orphazyme AS or generate 2.05% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Citigroup  vs.  Orphazyme AS

 Performance 
       Timeline  
Citigroup 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Citigroup are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating fundamental indicators, Citigroup exhibited solid returns over the last few months and may actually be approaching a breakup point.
Orphazyme AS 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Orphazyme AS are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Orphazyme may actually be approaching a critical reversion point that can send shares even higher in June 2024.

Citigroup and Orphazyme Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Citigroup and Orphazyme

The main advantage of trading using opposite Citigroup and Orphazyme positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Citigroup position performs unexpectedly, Orphazyme can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orphazyme will offset losses from the drop in Orphazyme's long position.
The idea behind Citigroup and Orphazyme AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stocks Directory
Find actively traded stocks across global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements